Latest Breaking News On - மூலதனம் ஆராய்ச்சி - Page 5 : comparemela.com

Subscribe Although product concentration remains a key risk where top 10 products contribute 66.36%, the company aims to reduce the dependence with planned capex in FY22, said a report by GEPL Capital Research. “We recommend a subscribe rating to the issue, considering strong research and development (R&D) capabilities, clean regulatory history, strong promoter backing with synergies and planned capex to drive medium term growth,” the report added. Advertisement Moreover, the company is benefiting from an anti-China product strategy going around the globe. “Except for one antimalarial product segment, our demand outlook, I mean demand that we are getting from customers from the last five quarters has been extremely solid. See, no one is saying that we are buying less from China and more from India, but it is very clear to see that kind of demand. So I believe China Plus One is a real thing,” said Yasir Rajwee, chief executive officer (CEO) of Glenmark Life Sciences in an

Tatva chintan pharmaYasir rajweeCapital researchGlenmark life sciencesGlenmark pharmaceuticalsGlenmark pharmaceuticalLife sciencesChina plus onePlus oneTatva chintan pharma chemதத்வா சிந்தன் பார்மாமூலதனம் ஆராய்ச்சிக்ளேண்மர்க் வாழ்க்கை அறிவியல்க்ளேண்மர்க் மருந்துகள்க்ளேண்மர்க் மருந்துவாழ்க்கை அறிவியல்